IL33 and hereditary elliptocytosis: Pravastatin inhibited H/R-induced organoid HE-based pathological damage (Figure 4B), decreased organoid vitality (Figure 4C), and increased LDH release (Figure 4D) in co-cultured WT-organoids and WT-ILC2s, but these effects were eliminated by anti-IL-33 or anti-ST2, and no effects were found in co-cultured IL-33−/− organoids and WT-ILC2s.